Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

P2116

Sigma-Aldrich

Pirfenidone

≥97% (HPLC), powder, antifibrotic agent

Synonym(s):

5-Methyl-1-phenyl-2-(1H)-pyridone

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
$127.98
50 MG
$573.07

$127.98

List Price$136.00Save 6%

In StockDetails


Request a Bulk Order

Select a Size

Change View
10 MG
$127.98
50 MG
$573.07

About This Item

Empirical Formula (Hill Notation):
C12H11NO
CAS Number:
Molecular Weight:
185.22
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

$127.98

List Price$136.00Save 6%

In StockDetails


Request a Bulk Order

Product Name

Pirfenidone, ≥97% (HPLC)

Quality Level

assay

≥97% (HPLC)

form

powder

solubility

H2O: >10 mg/mL at 60 °C (warming for 30 minutes)
DMSO: >20 mg/mL

originator

Shionogi

SMILES string

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChI key

ISWRGOKTTBVCFA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic[1] derivative of pyridine.[2]

Application

Pirfenidone has been used:
  • as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery[3]
  • as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit[2]
  • to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)[4]
  • as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia[5]

Biochem/physiol Actions

Inhibits collagen production and fibroblast proliferation.
Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival.[6] Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.[2]

Features and Benefits

This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

CX3CL1 (fractalkine) and TNF alpha production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling
Szukiewicz D, et al.
Inflammation Research, 63(3), 179-189 (2014)
Arata Azuma
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
Huzaifa I Adamali et al.
Drug design, development and therapy, 6, 261-272 (2012-10-12)
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)
Yangfan Yang et al.
PloS one, 8(2), e56837-e56837 (2013-02-26)
Posterior capsular opacification (PCO) is a common complication of cataract surgery. Transforming growth factor-β2 (TGF-β2) plays important roles in the development of PCO. The existing pharmacological treatments are not satisfactory and can have toxic side effects. We evaluated the effect

Articles

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

  1. What are storage conditions after receipt? I am unable to find in the website.

    1 answer
    1. According to Section 7 of the SDS, the item should be stored at room temp.

      Helpful?

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service